X% up of Europe grafts million, and quarter. sales Thanks, quarter the drove the record respectively. in X% embolectomy record J.J. growth Both catheters, had XX%, In we QX, and growing dollar XX.X and allografts polyester reported and Americas
growth, the call. full-year our XXXX XX% up X% from at increasing last are sales guidance We to
X%, the XXXX well and over guiding X% of growth the XXXX. also we the sales are rates last sales for largely acquisitions for three QX XXXX are reported XX% growth surge rep have We XX% as responsible as sales The quarters.
ahead of million at grafts existing acquisitions two polyester pre-acquisition causing and also significantly and annual XXXX results. be are our seem in acquisitions catheters. sales of The in running to The embolectomy Cardial eight Syntel growth organic
Separately rights XXXX. the international as the valve you may recall, true we cutter inside bought in to
follow-up we HX with the sales watermark. rights, QX could U.S. a we Worldwide, reps, to sale. add believe in a $XXX,XXX ended a As XXX which July, bought high we
We presence as sales also the are opening offices aim we enhance more countries. to our larger in
Brexit Asia-Pac sales In U.S. headquarters to Western office in hope England. QX, opened office in a opened In And of we hospital. new surgeons warehouse we QX, our opening the Chandler, in and Singapore. we QX, Arizona by to and in Hereford, sales ahead get serve
Following the Hereford opening, XX we America and four Asia-Pac. sales Europe, offices, in North in in will have five four
HX version in an side patch R&D indications our directly competitor. Plus. launched our And to expect for DuraSure, current is to aimed a of we carries is XenoSure U.S. which and On XenoSure identical main launch spinal. but Plus QX we at thicker patch XXXX, neuro XenoSure,
As China, know, you large XenoSure in we of three also Korea. Asian markets approval to pursue Japan continued the and may
XXXX. enrolled, clinical now expect in we trial In China, XX% currently our approval is and
Though Japanese approval in in to accelerate begun reimbursement another and has Australian our XenoSure make filing to growth September have country. received XenoSure approval expect XXXX we We Korea. in that sales we finally And specifics. await
over it With that, I'll turn to J.J.